ELI-002 for Colorectal Cancer
(AMPLIFY-7P Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new treatment called ELI-002 7P for patients with specific types of cancer. The treatment helps the immune system recognize and attack these cancer cells. ELI-002 7P targets mutations that are common in various cancers and have been studied for their role in tumor growth and resistance to treatments.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but you cannot use immunosuppressive drugs.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using immunosuppressive drugs.
What data supports the idea that ELI-002 for Colorectal Cancer is an effective treatment?
The available research does not provide any data on the effectiveness of ELI-002 for Colorectal Cancer. Instead, the studies focus on treatments for prostate cancer, specifically castration-resistant prostate cancer, and do not mention ELI-002 or its effectiveness for colorectal cancer or any other condition.12345
What safety data is available for ELI-002 in colorectal cancer treatment?
The provided research does not contain specific safety data for ELI-002, ELI-002 7P, or ELI-002 2P in the context of colorectal cancer treatment. The studies mentioned focus on other chemopreventive drugs and strategies, such as low-dose aspirin, COX-2 inhibitors, and dietary interventions, but do not address ELI-002 or its variants.678910
Eligibility Criteria
This trial is for people with certain solid tumors that have specific KRAS/NRAS mutations. They should show no signs of recurring disease on a CT scan, and some may need to have tumor DNA or high levels of cancer markers after standard treatments. It's not for those with treatable mutations, brain metastases, or who are taking immunosuppressive drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase 1A
Evaluation of Amph-Peptides 7P with Amph-CpG-7909 in subjects to determine dose for subsequent phases
Phase 1B
Dose expansion cohort to evaluate preliminary biomarker response in colorectal cancer subjects
Phase 2
Randomized evaluation of ELI-002 7P versus observation in PDAC subjects for antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ELI-002 7P
Find a Clinic Near You
Who Is Running the Clinical Trial?
Elicio Therapeutics
Lead Sponsor